About RedIF
We work collaboratively enhancing research, innovation and development within health sciences, and promoting educational activities.
Who We Are
The Red Iberoamericana de Farmacometría (RedIF) is an interdisciplinary scientific society founded in Montevideo, Uruguay, in November 2017. We represent the collaborative efforts of researchers, academics, industry professionals, and regulatory scientists from Argentina, Brazil, Chile, Colombia, Cuba, Mexico, Panama, Puerto Rico, Spain, Uruguay, and beyond.
Our network was born from a simple yet powerful idea: by joining forces across borders, we can accelerate the adoption of quantitative pharmacology and model-informed approaches throughout Latin America, ultimately improving public health outcomes across the region.
The Network
The Ibero-American Pharmacometrics Network was founded in 2017 as the natural association of research groups interest in the promotion and advancement of
the discipline of pharmacometrics in Latin America,
where still is an emergent science.
An international multidiscliplinary framework of collaboration was necessary to set common objectives and coordinate all efforts to disseminate modeling and simulation methodologies beyond academia, impacting industry and clinical areas.
Check out the Redif Statute
Our vision
To become a recognized Ibero-American network in the field of pharmacometrics through the promotion of education and training of personnel in this area and the encouragement of its application in the fields of development, registration, and use of medicines, integrating academia, industry, regulatory, and clinical sectors.
Our mission
Our mission is to promote the advancement of pharmacometrics in Latin America through its application in pharmacological research, enhancing drug development and the introduction of therapeutic strategies. We support dose optimization and rational use of medicines in clinical settings. Additionally, we aim to create a multidisciplinary framework for education and training of scientists entering this discipline.
Our objectives
RedIF pursues six core objectives:
Promote Pharmacometrics Development: Advance the application of pharmacometrics in research, innovation, drug development, approval, and introduction of new medications and therapeutic strategies throughout Ibero-America.
Disseminate Knowledge: Spread knowledge and advances in pharmacometrics across academic and professional environments related to human and veterinary health sciences in Ibero-America.
Foster Continuing Education: Drive continuous education in pharmacometrics, supporting teaching-learning processes that reduce barriers to knowledge such as language and lack of economic resources.
Strengthen Collaboration: Fortify collaboration between Ibero-American research groups in the field of pharmacometrics.
Create Regional Databases: Promote the creation of open-access Ibero-American population databases for use by health researchers in the development of pharmacometric studies.
Establish Institutional Links: Build institutional connections with national and international organizations with common interests and values, particularly with scientific associations.
Governing Board (2025-2026)
Directive Committee
President
Manuel Ibarra Viñales
Uruguay
Vice-President
Darlene Santiago
Puerto Rico
Treasurer
Iñaki F. Trocóniz
Spain
-
Nils Ramírez Arguedas
- Susanna Medellín Garibay
-
Mauricio García Alcalde
Fiscal Committee
Chair
Elba Romero
Member
Fausto Zaruma
Member
Marisín Pecchio
-
Natalia Riva
-
Jorge Duconge
-
Marcela Aragón
Our History: Timeline
Foundation of RedIF at the First RedIF Meeting and Workshop in Montevideo, Uruguay. Following discussions about an international call for proposals, Manuel Ibarra and Gonzalo Suárez invited Latin American researchers in pharmacometrics to gather in Montevideo for a workshop delivered by Iñaki F. Trocóniz and Marc Lavielle. In addition, a scientific activity was organized on the 5th day: “Simposio Internacional de Farmacometría en América Latina”, to showcase the current research being conducted by different groups in the region. During this historic meeting, the Red Iberoamericana de Farmacometría was officially born, with representatives from Uruguay, Spain, Brazil, Chile, Colombia, Cuba, and Mexico.
II RedIF Congress held in Guadalajara, Mexico. The first RedIF congress featuring internationally renowned speakers from around the globe, strategically connecting regional research with global disciplinary development. The event brought together 125 scientists from academia, industry, and regulatory agencies from 12 countries.
RedIF published its first scientific article: "Iberoamerican Pharmacometrics Network Congress 2018 Report: Fostering Modeling and Simulation Approaches for Drug Development and Regulatory and Clinical Applications in Latin America" in CPT: Pharmacometrics & Systems Pharmacology (DOI: 10.1002/psp4.12387)
April 22-27: First RedIF-ISoP Local Event in Montevideo, Uruguay: "Pharmacometrics Analysis with nlmixr"
July 8-13: Advanced Modeling Workshop in Panama City, Panama
September 27: Online Webinar: Basic Tools Course
October 27-30: III RedIF Congress in Havana, Cuba
Due to the COVID-19 pandemic, all activities moved to online formats:
August 29: Open Webinar: "Introduction to Virtual Bioequivalence"
October 13-16: Workshop: "Introductory Course on Pharmacometrics: Concepts, Nomenclature, and Applications" – A graduate-level course featuring a pharmacometrics showcase with student presentations
Online workshops replaced the in-person congress:
September 22-23: Hands-On Workshop: "Population PKPD Modeling & Simulation with the Monolix Suite"
October 13-16: RedIF Workshop 2021
October 7 & 21: Workshop: "Therapeutic Drug Monitoring & Pharmacometrics"
IV RedIF Congress in Porto Alegre, Brazil. The concept of establishing a formal scientific society emerged, and the decision was made to hold RedIF congresses biennially (every two years).
March 16-17: Online TDM Workshop 2022
April 29-May 1: Online Workshop RedIF 2022
May 5: RedIF contributed to organizing World Smart Medication Day 2022 (online), featuring "New Pharmacology Tools for the Development of Precision Medicine"
RedIF published its second article: "Barriers to global pharmacometrics: educational challenges and opportunities across the globe" following discussions at WCoP 2022 (World Conference on Pharmacometrics). The article examines educational gaps and training disparities obstructing pharmacometrics growth worldwide.
August 17: Precision Dosing Local Event in Guadalajara, Mexico
December 4: "Pharmacometrics and Modeling in the National Pharmaceutical Ecosystem" event in Santiago, Chile
V RedIF Congress in Bogotá, Colombia. The congress consolidated the vision of establishing RedIF as a formal scientific society.
October 25: RedIF contributed to the scientific publication "Modeling and Simulations in Latin-American Generic Markets: Perspectives from Chilean Local Industry, Regulatory Agency, and Academia" in Molecular Pharmaceutics, providing regional perspectives on implementing M&S in generic drug development.
RedIF officially incorporated as a civil association (asociación civil) with statutes approved and signed by founding members.
VI RedIF Congress scheduled for 2026 in Chile
Why Pharmacometrics Matters in Latin America
Pharmacometrics and systems pharmacology have emerged as transformative paradigms in drug discovery and development globally. Model-informed decisions reduce economic costs, improve ethical standards by optimizing clinical trial designs, and extract meaningful information from data far beyond traditional statistical approaches.
For developing regions like Latin America, these approaches represent "an opportunity to bring modern methods into play" (Pillai et al., 2013) and advance drug development, therapeutic strategies, and pharmaceutical innovation in our countries.
Regional Context and Opportunities:
Recent research has highlighted both the challenges and immense potential of pharmacometrics in Latin America:
Generic Drug Development
The Latin American pharmaceutical industry primarily focuses on manufacturing and developing generic drug products. Modeling and simulation approaches can significantly enhance the rational development of bioequivalent generics (García et al., 2024).
Educational Infrastructure
While the potential of Model-Informed Drug Development (MIDD) is clear in the region, implementation requires addressing educational challenges and building a critical mass of trained pharmacometricians (Michelet et al., 2023).
Regulatory Innovation
Pioneering initiatives like ANVISA's (Brazilian Health Regulatory Agency) guidance on Physiologically Based Pharmacokinetic (PBPK) modeling demonstrate the region's commitment to embracing quantitative pharmacology in regulatory science.
The implementation, standardization, and acceptance of pharmacometrics requires concerted effort through scientific exchange and collaboration among all stakeholders—exactly what RedIF provides.
Membership Categories
RedIF welcomes various types of members: